| Deane, Kevin |
| Recruiting | N/A | 750 | US | | University of Colorado, Denver | Rheumatoid Arthritis, Interstitial Lung Disease | 06/27 | 06/27 | | |
| Moreland, Larry W |
| Active, not recruiting | 2 | 104 | NA | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Rheumatoid Arthritis | 08/25 | 03/26 | | |
NCT06201416: Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis |
|
|
| Recruiting | 1 | 24 | US | SBT777101 | Sonoma Biotherapeutics, Inc. | Rheumatoid Arthritis | 03/26 | 03/26 | | |
| Feser, Marie |
| Recruiting | N/A | 125 | US | No intervention | Northwestern University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Michigan, Hospital for Special Surgery, New York, University of Colorado, Denver, Johns Hopkins University | Arthritis, Rheumatoid, Pain | 02/26 | 04/26 | | |
| Wagner, Elizabeth J |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
GLEAM, NCT06294236: Study Evaluating SC291 in Subjects with Severe R/r B-cell Mediated Autoimmune Diseases |
|
|
| Recruiting | 1 | 36 | US | SC291, Cyclophosphamide, Fludarabine | Sana Biotechnology | Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis | 12/27 | 03/28 | | |
| Recruiting | N/A | 1200 | Canada, US | Kidney Biopsy | University of Michigan, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The NephCure Foundation | Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental | 06/26 | 06/26 | | |
| Podoll, Amber |
| Terminated | 3 | 270 | Europe, Japan, US, RoW | Bardoxolone methyl, RTA 402 | Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc. | Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney | 08/23 | 08/23 | | |
| Terminated | 3 | 667 | Europe, Japan, US, RoW | Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule | Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC | Autosomal Dominant Polycystic Kidney, ADPKD | 08/23 | 08/23 | | |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
GLEAM, NCT06294236: Study Evaluating SC291 in Subjects with Severe R/r B-cell Mediated Autoimmune Diseases |
|
|
| Recruiting | 1 | 36 | US | SC291, Cyclophosphamide, Fludarabine | Sana Biotechnology | Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis | 12/27 | 03/28 | | |
| Recruiting | N/A | 1200 | Canada, US | Kidney Biopsy | University of Michigan, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The NephCure Foundation | Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental | 06/26 | 06/26 | | |
| Scheffel, Jenny |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
| Clauw, Andrew |
| Active, not recruiting | 2 | 104 | NA | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Rheumatoid Arthritis | 08/25 | 03/26 | | |
NCT06201416: Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis |
|
|
| Recruiting | 1 | 24 | US | SBT777101 | Sonoma Biotherapeutics, Inc. | Rheumatoid Arthritis | 03/26 | 03/26 | | |
| Sahakian, Lori |
| Recruiting | 3 | 420 | Europe, Canada, US, RoW | ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 03/27 | 07/30 | | |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 1/2 | 30 | US, RoW | IMPT-514 | ImmPACT Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 02/27 | 02/27 | | |
